FTSE 100 shares are frequently described as cheap by analysts, and have been for a while. That’s often backed up by the price-to-earnings, the price-to-sales ratio, and the price-to-book ratio.
However, we shouldn’t invest because of a company’s performance last year. And we’re not investing just for the next 12 months. It’s about how a company will perform throughout the medium and long term.
PEG ratios
Thus, growth is central to the equation. That’s where the PEG ratio can help us. This metric provides a valuable tool for investors seeking to assess a company’s growth potential in relation to its current valuation.
The PEG ratio, or price/earnings-to-growth ratio, takes into account both the price-to-earnings (P/E) ratio and the expected earnings growth rate.
A PEG ratio of 1 is often considered indicative of fair value, suggesting that the stock’s price is in line with its anticipated growth.
Ratios below 1 may suggest that the stock is undervalued relative to its growth prospects, while ratios some distance above 1 may indicate potential overvaluation.
Nonetheless, this is just a rule of thumb and it’s often prudent to compare companies within the same sector. For example, the PEG ratio is often calculated using annualised growth rates over five years and some industries may see tailwinds further into the long run.
By incorporating expected earnings growth into the assessment, the PEG ratio offers a more comprehensive view than the P/E ratio alone. This is particularly relevant in industries or sectors where high-growth companies might justify higher valuations.
FTSE 100 shares with low PEGs
As noted above, it can pay to compare companies within the same industry. However, the below data provides us with an insight into some of the cheapest stocks on the index. This is just a handful of stocks with PEG ratios that looks pretty attractive.
PEG Forward
AstraZeneca
1.5
Burberry
1.4
Hikma
1.2
Lloyds
0.5
Rolls-Royce
0.5
Smith & Nephew
1.4
FTSE 100 shares: PEG ratios
This PEG data can be used as the basis to make informed investment decisions. However, the PEG ratio does have one main drawback. That’s the fact it’s reliant on estimated future growth rates. These estimates are subjective and can vary among analysts, introducing a degree of uncertainty into the calculation.
However, the above data broadly reiterates widely-shared sentiment that companies like Lloyds and Rolls-Royce are undervalued. It also provides us with important data about stocks that are less frequently considered, including generics manufacturer Hikma.
AstraZeneca is another interesting company to see on this list. The pharma giant trades around 30 times earnings, but analysts anticipate this R&D-driven business to continue growing an impressive rate throughout the medium term.
It’s also possible that AstraZeneca, Hikma, and Smith & Nephew will continue growing strongly beyond the medium term. This is because there’s a broad understanding that ageing global populations will cause demand for new drugs, generic products, and medical devices, to surge.
As such, from my notes above, it’s clear that the PEG ratio is good starting point for assessing stocks and making informed investment decisions.
The post What do low PEG ratios tell us about these FTSE 100 shares? appeared first on The Motley Fool UK.
5 stocks for trying to build wealth after 50
Inflation recently hit 40-year highs… the ‘cost of living crisis’ rumbles on… the prospect of a new Cold War with Russia and China looms large, while the global economy could be teetering on the brink of recession.
Whether you’re a newbie investor or a seasoned pro, deciding which stocks to add to your shopping list can be a daunting prospect during such unprecedented times. Yet despite the stock market’s recent gains, we think many shares still trade at a discount to their true value.
Fortunately, The Motley Fool UK analyst team have short-listed five companies that they believe STILL boast significant long-term growth prospects despite the global upheaval…
We’re sharing the names in a special FREE investing report that you can download today. We believe these stocks could be a great fit for any well-diversified portfolio with the goal of building wealth in your 50’s.
Claim your free copy now
setButtonColorDefaults(“#5FA85D”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#43A24A”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#ffffff”, ‘color’, ‘#FFFFFF’);
})()
More reading
These FTSE 100 banks appear massively undervalued! Are they?
How to try and turn £450 a month into £1m using a SIPP
I’d copy Warren Buffett’s tactics and start buying cheap growth stocks
Buy-to-let is dying! Here’s how I’d earn a second income with £10k
How cheap is the Lloyds share price?
James Fox has positions in AstraZeneca Plc, Lloyds Banking Group Plc and Smith & Nephew Plc. The Motley Fool UK has recommended AstraZeneca Plc, Burberry Group Plc, Hikma Pharmaceuticals Plc, Lloyds Banking Group Plc, and Smith & Nephew Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.
